EBS vs PCRX

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Jul 15, 2026

EBS

50.6
AI Score
VS
PCRX Wins

PCRX

56.8
AI Score

Investment Advisor Scores

EBS

51score
Recommendation
HOLD

PCRX

57score
Recommendation
HOLD

AI Analyst Insights

Detailed Metrics Comparison

Metric EBS PCRX Winner
Forward P/E 2.0773 8.7184 EBS
PEG Ratio 0.3835 11.2121 EBS
Revenue Growth -29.7% 5.0% PCRX
Earnings Growth -93.8% -30.0% PCRX
Tradestie Score 50.6/100 56.8/100 PCRX
Profit Margin -1.3% 0.7% PCRX
Beta 1.00 1.00 Tie
AI Recommendation HOLD HOLD Tie

Relative Price Performance (Last 90 Days)

EBS 1M: -10.5% · 3M: -12.5% PCRX 1M: +6.0% · 3M: +10.1%

Current Technical Phase

EBS

Markdown
Sell / avoid

Price below a falling SMA50 (slope -3.8%), weak momentum, RSI 42

RSI (14): 42.3 · Price: $7.41

PCRX

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (3.3% over 20 days), RSI 64

RSI (14): 64.0 · Price: $26.92

Fundamentals Snapshot

Metric EBS PCRX
Market Cap
Forward P/E 8.1 7.4
Trailing P/E 203.2
Revenue (TTM)
Revenue Growth -0.3% 0.1%
Gross Margin 0.5% 0.8%
Operating Margin 0.1% 0.0%
EPS -0.19 0.13
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, PCRX is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.